Copyright
©The Author(s) 2023.
World J Gastroenterol. Apr 14, 2023; 29(14): 2078-2100
Published online Apr 14, 2023. doi: 10.3748/wjg.v29.i14.2078
Published online Apr 14, 2023. doi: 10.3748/wjg.v29.i14.2078
Ref. | Probiotics | Prebiotics | Dose | Parameters analyzed | Conclusion |
Amiriani et al[86], 2020 | Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophiles | FOS | Lactocare capsule twice daily for 8 wk | DAI | Mitigated symptoms in patients with UC and suggested to use pre-probiotics in the standard treatment, particularly in those with more than five years of the disease |
Kamarlı Altun et al[87], 2019 | Enterococcus faecium, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Bifidobacterium longum | FOS | 3 × 109 CFU probiotic and 225 mg/tablet prebiotic for 8 wk | Hemoglobin, leukocyte, neutrophil-to-lymphocyte ratio, sedimentation, and CRP and clinical and endoscopic activity indices | Improvement in clinical activity |
- Citation: Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29(14): 2078-2100
- URL: https://www.wjgnet.com/1007-9327/full/v29/i14/2078.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i14.2078